Plain-English translation of NCT06812481 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how medications with anticholinergic properties—a common side effect of many drugs—might affect bone density and fracture risk in people with rheumatoid arthritis. The study will look at your medical records, blood work, and bone density scans you may have already had to see if there's a connection between the burden of these medications and weaker bones.
Many people with rheumatoid arthritis take multiple medications that can have anticholinergic effects as a side effect. Doctors want to know if this 'medication burden' might be contributing to bone loss and higher fracture risk—information that could help them choose safer medication combinations for their patients.
You likely qualify if…
You likely don't qualify if…
You would allow researchers to review your existing medical records, including your blood test results, bone density scan results, and a list of all your current medications. They will use special scoring tools to measure how much anticholinergic burden you're carrying and assess your fracture risk based on standard guidelines. This is a non-invasive study—no new procedures or medications—just a review of information you've already had collected.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Turkey (Türkiye)
Enrollment target
~100 participants
Started
September 2025
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bilal UYSAL, assistant professor
Balikesir University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.